Literature DB >> 15531230

Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy.

Steve M M de Castro1, Koert F D Kuhlmann, N Tjarda van Heek, Olivier R C Busch, G Johan Offerhaus, Thomas M van Gulik, Hugo Obertop, Dirk J Gouma.   

Abstract

The survival rate after microscopically radical resection of pancreatic duct adenocarcinoma is still poor. Patients with ampulla of Vater and distal common bile duct adenocarcinoma indicate a much more favorable prognosis. Controversy exists as to whether adjuvant therapy could improve the outcome in these patients after resection. The aim of the present study was to analyze the pattern of recurrence in patients with periampullary adenocarcinoma after pancreatoduodenectomy. Between January 1992 and December 2002, all patients with an R0 resection were identified and used for this analysis. A total of 190 patients underwent a microscopically radical resection and received no adjuvant therapy. Of those, 72 patients were diagnosed with pancreatic duct adenocarcinoma, 86 patients were diagnosed with ampulla of Vater adenocarcinoma, and 31 patients were diagnosed with distal common bile duct adenocarcinoma. Recurrent disease was indicated in 81% of the patients with pancreatic duct adenocarcinoma, 50% of the patients with ampulla of Vater adenocarcinoma, and in 74% of the patients with bile duct adenocarcinoma. Multivariate analysis revealed that lymph node metastases were prognostic for recurrent disease in patients with pancreatic duct adenocarcinoma (P = 0.038). The depth of invasion (T4, P < 0.032) and lymph node metastases (P < 0.001) were prognostic in patients with ampulla of Vater adenocarcinoma. Poor tumor differentiation (P < 0.001) was prognostic in patients with distal bile duct adenocarcinoma. Selected patients with periampullary malignancies exhibited a high recurrence rate and should be encouraged to enroll in clinical trials for adjuvant treatment including local therapy (radiotherapy) according to the identified prognostic factors.

Entities:  

Mesh:

Year:  2004        PMID: 15531230     DOI: 10.1016/j.gassur.2004.08.006

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  37 in total

1.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

Review 2.  A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer.

Authors:  S Pedrazzoli; H G Beger; H Obertop; A Andrén-Sandberg; L Fernández-Cruz; D Henne-Bruns; J Lüttges; J P Neoptolemos
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

Review 3.  General aspects of surgical treatment of pancreatic cancer.

Authors:  S Pedrazzoli; C Pasquali; C Sperti
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

4.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

5.  Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival.

Authors:  S M M de Castro; N T van Heek; K F D Kuhlmann; O R C Busch; G J A Offerhaus; T M van Gulik; H Obertop; D J Gouma
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

6.  Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation.

Authors:  Jeffrey D Wayne; Eddie K Abdalla; Robert A Wolff; Christopher H Crane; Peter W T Pisters; Douglas B Evans
Journal:  Oncologist       Date:  2002

Review 7.  Complications of pancreatic cancer resection.

Authors:  C M Halloran; P Ghaneh; L Bosonnet; M N Hartley; R Sutton; J P Neoptolemos
Journal:  Dig Surg       Date:  2002       Impact factor: 2.588

8.  Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection.

Authors:  J G Fortner; D K Kim; A Cubilla; A Turnbull; L D Pahnke; M E Shils
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

9.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more
  19 in total

1.  Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.

Authors:  Bolanle Asiyanbola; Ana Gleisner; Joseph M Herman; Michael A Choti; Christopher L Wolfgang; Michael Swartz; Barish H Edil; Richard D Schulick; John L Cameron; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-12-17       Impact factor: 3.452

2.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

3.  Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

Authors:  John W Nelson; A Paiman Ghafoori; Christopher G Willett; Douglas S Tyler; Theodore N Pappas; Bryan M Clary; Herbert I Hurwitz; Johanna C Bendell; Michael A Morse; Robert W Clough; Brian G Czito
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-19       Impact factor: 7.038

4.  Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database.

Authors:  Veronica G Onete; Marc G Besselink; Chanielle M Salsbach; Casper H Van Eijck; Olivier R Busch; Dirk J Gouma; Ignace H de Hingh; Egbert Sieders; Cornelis H Dejong; Johan G Offerhaus; I Quintus Molenaar
Journal:  HPB (Oxford)       Date:  2015-06-02       Impact factor: 3.647

5.  Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater.

Authors:  Isao Kurosaki; Masahiro Minagawa; Chie Kitami; Kabuto Takano; Katsuyoshi Hatakeyama
Journal:  Langenbecks Arch Surg       Date:  2011-02-24       Impact factor: 3.445

6.  Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.

Authors:  Kyubo Kim; Eui Kyu Chie; Jin-Young Jang; Sun Whe Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

7.  CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.

Authors:  Kyubo Kim; Hye Sook Min; Eui Kyu Chie; Jin-Young Jang; Sun Whe Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Ja-June Jang; Sung W Ha
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

8.  Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.

Authors:  Jan Franko; Alyssa M Krasinskas; Marina N Nikiforova; Narcis O Zarnescu; Kenneth K W Lee; Steven J Hughes; David L Bartlett; Herbert J Zeh; A James Moser
Journal:  J Gastrointest Surg       Date:  2008-08-02       Impact factor: 3.452

9.  Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?

Authors:  E V Tsvetkova; T R Asmis
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

10.  Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater.

Authors:  Laurence Chiche; Barbara Alkofer; Jean-Jacques Parienti; Vincent Rouleau; Ephrem Salamé; Guy Samama; Philippe Segol
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.